Related Experiment Video
Updated: Sep 17, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Predictive model for ulcerative colitis therapeutic response using clinical indicators and peripheral blood T-cell
Tian Pu1, Chunru Wang1, Ranran Feng1
1Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Objective:
This study aimed to integrate clinical indicators with peripheral blood T-cell subsets to develop a prediction model for ulcerative colitis (UC), and to facilitate precise subtyping and individualized treatment decisions.
Methods:
A retrospective cohort of 346 UC patients (June 2023-June 2025) was randomly assigned to training (n=242) and validation (n=104) sets at a 7:3 ratio. Univariate analysis, Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression to identify independent influencing factors. Machine learning models-random forest (RF), gradient boosting, and logistic regression-were constructed using the selected core variables. Model discrimination, calibration, and clinical utility were assessed using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA).
Results:
According to week-14 response criteria, the training set comprised 158 responders (65.3%) and 84 non-responders (34.7%). Six indicators significantly associated with treatment response: albumin, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), CD3+CD4+CD25+/CD3+CD4+ T-lymphocyte ratio, and CD4/CD8 ratio were as independent influencing factors. Among the models, RF exhibited the highest numerical AUC, with an AUC of 0.852 in the training set and 0.804 in the validation set. The calibration curve demonstrated good agreement between predicted and actual risks. DCA indicated higher net clinical benefit within a risk threshold range of 0.1-0.8.
Conclusion:
A predictive model for UC treatment response based on clinical indicators and peripheral blood T-cell subsets was constructed and validated, and may serves as an exploratory tool for individualized treatment decisions in UC.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Clinical Manifestations
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Crohn's Disease